The Vision is Clear: First Data from TTX Ophthalmic Franchise

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

A “platform technology”.

The first thing that you’d see on a company slide deck… but the furthest thing from reality for most.

All biotechs have an element of being a platform technology.

Drugs or medical devices can show promise across many different applications, indications, and targets.

… but very few companies are built platform-first.

Just because a product has platform potential… doesn’t make it a platform company.

For investors, a true platform technology is the “holy grail”.

Build it once, and then multiple applications follow.

It is capital-light.

Scaleable.

But incredibly hard to execute.

A platform company has a different risk profile.

It’s not just about the capabilities of the underlying technology…

But also about finding the right commercial partners to take the product forward.

A platform technology only works if the company itself is built platform-first.

That is the story of my first-ever Armchair Pick, Tetratherix (ASX: TTX).

Six different markets.

One single technology.

A polymer that can act as a nasal spray for GLP-1 delivery… but also as a spacer for cancer surgery.

Bone healing for teeth… and also holding the eye in shape during cataract surgery.

The applications are bountiful because the polymer itself is smart.

Think of it like medical LEGO.

Different tissue, different opacity, different stability.

Same underlying tech.

From all of TTX’s products, the one that best embodies the platform ethos is Optimatrix.

The product for cataract surgery.

But first…

Congratulations to a friend of the newsletter, Mark Pachacz at Bioshares, for Edition #1000.

It is a paid service, but I do love reading what Mark has to say about the ASX healthcare industry every two weeks.

Mark has allowed me to share a complimentary copy of this week’s edition.

Tetratherix (ASX: TTX) successfully completed a preclinical study of Optimatrix for cataract surgery. (TTX, held, Armchair Pick)

🪑 Milestone ticked!

HeraMED (ASX: HMD) secures full-scale commercial deployment of its maternity solution with Lee Health. (HMD)

🪑 Huge milestone, well done.

EBR Systems (ASX: EBR) will submit to the FDA to update labelling on the WiSE System, focusing on echo-induced pacing risks and mitigation strategies. (EBR)

🪑 An important follow-up to the safety issues that emerged from the incorrect use of the EBR pacemaker with an echo.

Adherium (ASX: ADR) secures a term loan of AUD $4.67M from Trudell Medical for working capital. (ADR)

🪑 It appears that Trudell will finance this into oblivion.

EMVision (ASX: EMV) completes a successful trial of its First Responder brain scanner in Australia's first mobile stroke unit; it achieved its primary usability and workflow objectives. (EMV)

🪑 A great first step toward EM Vision's holy grail: a portable stroke scanner in every ambulance in the world.

Talius Group Limited (ASX: TAL) announces the resignation of Founder and Executive Director Graham Russell. (TAL)

🪑 Good innings from Graham.

Ceretas Limited (ASX: CTS) completes a number of technical developments on its dementia product that unlocked ~$700K funding tranche from Brandon BioCatalyst. (CTS)

This morning, TTX published the first independent preclinical data for Optimatrix.

Optimatrix is a fully synthetic gel designed to hold the eye in shape and protect it during cataract surgery.

Cataract surgery is one of the most common surgeries in the world.

20 million a year.

3.7 million in the US and 7 million in Europe.

Virtually every surgery uses the same type of device to hold the eye in place.

An OVD, or an Ophthalmic Viscosurgical Device.

It is a clear gel injected through the same small incision, which fills the chamber inside the eye and helps maintain its shape.

At the end of the operation, the OVD is washed and suctioned back out.

Think of the eye like a grape.

If you remove some of the juices inside, the pressure reduces, and you're left with just the thin grape skin.

That's what an OVD prevents.

It helps keep the eye's shape.

The challenge is that the devices that best protect the eye (and hold its shape) are the hardest to remove.

The ones that are easier to remove… well, those don’t protect the eye or hold its shape.

This is the central trade-off in cataract surgery.

“Protect the Eye” vs “Easy to Remove”.

TTX’s product does BOTH.

It starts off in liquid form and then, using the heat from the patient’s eye, turns into a gel.

To wash it out, the surgeon uses cooled saline to turn the gel back into a liquid, making it much easier to remove.

It basically works against every rule of thermodynamics that I learned in Year 9 physics.

But hey... 

That’s the magic of this product.

Surgeons have adapted to the trade-off.

(Essentially through specialist training and a steady hand to use the “harder to remove” products).

But the industry can’t adapt to the supply chain issue immediately.

Every OVD needs three key things:

Over the last few decades, innovation in the field has been limited.

The global OVD market is worth around US$3 billion, with Alcon controlling roughly 55%.

A key material used in part of Alcon’s OVD portfolio?

Shark fins… from a single supplier in China.

Susceptible to tariffs.

Susceptible to ESG groups.

Susceptible to a supply chain crunch.

A HUGE supply chain risk.

Enter TTX.

Late last year, TTX’s ophthalmic joint venture BioOptix signed a deal with Alcon.

The deal was that Alcon would provide funding through its corporate grant program, “subject to agreed development milestones”.

… well, TTX just delivered a major preclinical milestone today.

E&P also reported in its Initiation of Coverage Note that the agreement contained a “Capital T Transaction” clause.

This essentially allowed Alcon to acquire or take an exclusive licence over BioOptix before FDA approval.

TTX had a buyer lined up before the product had barely moved on from an “idea”.

The perfect Platform Play.

TTX has structured its entire business platform first.

The ophthalmology spacer product that I’ve been talking about is NOT being developed by TTX itself.

But rather, it’s its JV partner, BioOptix.

BioOptix is a joint venture between Tetratherix and a group of ophthalmologists in the US.

The EXACT key opinion leaders you would hope to secure when starting to commercialise a product like this.

TTX owns between 15% and 20% of BioOptix.

TTX’s job is to supply the tech.

BioOptix's job is to finance the development pathway and prove that it works.

… it’s essentially a free roll for TTX.

Now.

The end goal is a takeout from Alcon… there is no doubt about that.

That would provide TTX with a nice uplift on its equity investment in BioOptix.

Cool.

But the real prize for TTX is the supply agreement already negotiated into the BioOptix structure.

It’s important, so let me repeat.

There is a supply agreement, already negotiated, that IF the product goes to market, TTX will be the one selling the core ingredient to Alcon.

So…

IF, this product is successfully commercialised.

AND, BioOptix is bought out by Alcon.

THEN, TTX receives a major supply agreement with the #1 supplier of OVDs to the cataract surgery market.

AND, TTX will have a group of US ophthalmologists and key opinion leaders already onside to help push the device into the market.

That is the corporate genius of this arrangement.

And the Platform Playbook.

All TTX needs to do is usher the franchise along and make sure it has enough manufacturing capacity when the product is ready to go to market.

At the end of it (assuming it goes well), TTX should get a nice payday on its BioOptix investment AND a major supply agreement with Alcon.

All without funding the clinical trials from its own balance sheet.

That’s on BioOptix.

Optimatrix is a Class III medical device.

That means the full PMA pathway is required, which is the FDA’s most demanding route to approval.

TTX has already engaged the FDA through a pre-submission to confirm the product code and required preclinical studies.

The formal preclinical study is now underway, with Optimatrix compared head-to-head against the standard of care over 90 days.

But today’s announcement answered the first question:

Can the eye tolerate Optimatrix if some of the gel is accidentally left behind after surgery?

The answer: yes.

On these measures, TTX’s product reached the same pressure as the control, but settled much quicker.

Interestingly, each animal acted as its own control.

Optimatrix in one eye, and the other eye underwent a sham procedure using a balanced salt solution, which was removed as normal.

What TTX was able to show was…

The gel remained clear. Tick

The chamber was held throughout the operation. Tick.

Eye pressure returned to its pre-operative level within six hours. Tick.

And despite leaving 100% of the product inside the eye, pressure had not risen again after 48 hours. Big safety tick.

Next steps are:

I would also suspect BioOptix will need to raise more capital to finance those upcoming trials.

Again, Alcon’s “Capital T Transaction” clause allows it to acquire or take an exclusive licence over BioOptix at any point BEFORE FDA approval.

TTX’s sexiest product is the nasal spray for GLP-1 delivery.

TTX’s closest product to FDA approval is the bone-healing franchise.

But in my opinion, better than any of the other franchises, Optimatrix demonstrates the strategic value of being a “platform play”.

I love this chart that TTX publishes because it really demonstrates the strategy:

A capital-light model to get products to market.

It’s amazing to think that the proof-of-concept work for Optimatrix only started in 2024.

And the company is already moving into formal preclinical development, with the world’s largest OVD supplier funding the journey.

TTX develops the platform.

Its partners finance the pathway.

And if everything works… TTX supplies the product.

That is what a platform-first company looks like.

… and this is just one of six businesses that TTX will be a part of.

See you all tomorrow,

The Armchair Analyst

What is an armchair pick?

An Armchair Pick is an invite-only spot I reserve for my highest-conviction investment ideas.

It's a paid arrangement, but to align myself, I only take my fee in shares - half escrowed for 6 months, half for 12.

It is general commentary only, not personal financial advice or a recommendation to buy, sell, or hold. Always see the disclosure at the top of the article and do your own research.